LZCap™ AG(3'Acm) is a Cap1 analog, can be used as the capping agent for producing mRNAs in an "one-pot"process. Under the action of T7 polymerase, mRNA with 5' end Cap 1 structure was generated by cotranscription using LZCap™ AG(3'Acm), NTPs, and template DNA. The capped mRNA could be directly translated and expressed in cells and in vivo. It is widely used in the fields of in vitro transcription, gene editing, vaccine development, tumor CAR-T therapy, protein substitution therapy and regenerative medicine.LZCap™ AG(3'Acm) requires the T7 promoter with AG as the starting sequence. LZCap™ AG(3'Acm) can provide>97%capped mRNA, and up to 100-200 μg capped mRNA can be generated with 1 μg DNA template per standard reaction Specifications Cat.No. 10684ES60/10684ES80 Size 100 μL/1 mL Molecular Formula C35H48N16O24P4（Free acid） Molecular Weight 1200.75（Free acid） Concentration 100 mM Purity HPLC ≥90% Salt type NH4+ Structure Components Name 10684ES60 10684ES80 LZCap™ AG(3'Acm) GMP-grade (100 mM) 100 μL 1 mL Figures 1. High Yield and Capping Efficiency of LZCap With LZCap AG(3'Acm) cap, the luciferase mRNA capping efficiency is about 97.59%, and up to 200 μg capped mRNA can be obtained with 1 μg DNA template in a standard in vitro transcription (IVT) reaction with T7 RNA polymerase. The mRNA purity is up to 99% after simple LiCl precipitation. This high capping efficiency and yield make LZCap an attractive option for various applications, including protein production and gene therapy. Product Cap AG (3'-OMe-7mG) LZCap AG(3'Acm) AG (no capping) mRNA yield (μg) 164 173 200 Figure 1. MS analysis of the capping efficiency of LZCapped Luciferase mRNA with RNAse H based method. The capping efficiency is about 97.59%.
Related
Related
Related
Related